Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Impax

- PMLiVE

GSK’s shingles vaccine Shingrix claims US approval

Becomes first alternative to Merck & Co’s Zostavax

- PMLiVE

Pfizer could raise ‘up to $15bn’ from consumer unit sale

Would follow in the footsteps of Novartis, Boehringer and Merck & Co if it does strike a deal

- PMLiVE

Former GSK CEO joins Synthego’s advisory board

Sir Andrew Witty will expand the team’s bioinformatics expertise

- PMLiVE

With US approval, GSK now needs rapid uptake for COPD triple

Aims to quickly launch the predicted blockbuster to revive its R&D portfolio

- PMLiVE

GSK’s Shingrix sails through FDA advisory committee

Shingles vaccine data proved safe and effective, says the panel

- PMLiVE

GSK preps COPD filing for asthma pioneer Nucala

Moves despite reporting mixed data for the treatment earlier this year

- PMLiVE

Ionis must go it alone as GSK ditches polyneuropathy drug

Inotersen’s side effects prompts pharma giant to relinquish rights

GSK hands new chief digital officer a transformative remit

Karenann Terrell will join the pharma firm from Walmart

- PMLiVE

GSK’s pipeline cull claims sirukumab, and possibly rare disease unit

Makeover designed to deliver a leaner, fitter company in 2020

- PMLiVE

Mitsubishi buys Israel’s NeuroDerm for $1.1bn

The deal will see it focus on a series of drug-device combinations for Parkinson’s disease, headed by phase III candidate ND0612

- PMLiVE

Shake-up at GSK could claim antibiotics unit and UK facilities

The firm says its plans, which are expected to lead to 320 job cuts, are not related to Brexit

GSK signs up to apply AI to drug discovery

Will work with Exscientia on 10 small molecule targets

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links